Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 397
Rating:

Prof Marion Subklewe - University of Munich, Munich, Germany

Prof Marion Subklewe speaks to ecancer at ASH 2018 about the phase 1 study into AMG330, an anti-CD33 bispecific T-Cell engager antibody construct, in relapsed/refractory AML.

She explains that the issue with the T cell antibody construct is cytokine release syndrome however these side effects were expected and dose steps were introduced in order to alleviate this.

Prof Subklewe reports that, although it is at an early stage, the study has seen some complete remissions in some of the higher doses.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation